{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:40:38Z","timestamp":1782949238791,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clineuro.2024.108615","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:37:36Z","timestamp":1729618656000},"page":"108615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar"],"prefix":"10.1016","volume":"247","author":[{"given":"Beatriz Garcia","family":"Ca\u00f1ibano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7184-1235","authenticated-orcid":false,"given":"Lina","family":"Okar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya Zakarya","family":"Baniamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Deleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2024.108615_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40120-020-00187-3","article-title":"Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing\u2013remitting multiple sclerosis patients? A narrative review","volume":"9","author":"AlSharoqi","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clineuro.2024.108615_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo\u2013controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2024.108615_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40120-019-0129-0","article-title":"An overview of high-efficacy drugs for multiple sclerosis: gulf region expert opinion","volume":"8","author":"Alroughani","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clineuro.2024.108615_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/03007995.2019.1669378","article-title":"Management of relapsing\u2013remitting multiple sclerosis in Qatar: an expert consensus","volume":"36","author":"Deleu","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.clineuro.2024.108615_bib7","unstructured":"European Medicines Agency, 2017. Mavenclad. Summary of Product Characteristics. Available at https:\/\/www.ema.europa.eu\/documents\/product\u2013information\/mavenclad\u2013epar\u2013product\u2013information_en.pdf (accessed July 2023)."},{"key":"10.1016\/j.clineuro.2024.108615_bib8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108615_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/13524585211010294","article-title":"Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies","volume":"28","author":"De Stefano","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2024.108615_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long\u2013term use of cladribine tablets for multiple sclerosis: systematic literature review of real\u2013world evidence","volume":"69","author":"Oreja\u2013Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib11","first-page":"693","article-title":"Two year relapse\u2013free and NEDA status with cladribine in a real\u2013life population: a multicentre study.","volume":"27","author":"Annovazzi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2024.108615_bib12","first-page":"795","article-title":"4\u2013year follow\u2013up of multiple sclerosis patients treated with cladribine: clinical outcomes and third\u2013year course.","volume":"29","author":"Oreja\u2013Guevara","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108615_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long\u2013term effectiveness in patients previously treated with cladribine tablets: a real\u2013world analysis of the Italian multiple sclerosis registry (CLARINET\u2013MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.clineuro.2024.108615_bib16","article-title":"Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks","volume":"2016","author":"Alroughani","year":"2016","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.clineuro.2024.108615_bib17","article-title":"Family planning for people with multiple sclerosis in Saudi Arabia: an expert consensus","volume":"2021","author":"Al Jumah","year":"2021","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.clineuro.2024.108615_bib18","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease\u2013modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108615_bib19","first-page":"1273","article-title":"Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta\u2013analysis, and meta\u2013regression","volume":"27","author":"Mardan","year":"2021","journal-title":"J. Manag. Care. Spec. Pharm."},{"key":"10.1016\/j.clineuro.2024.108615_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40120-021-00260-5","article-title":"Expert consensus and narrative review on the management of multiple sclerosis in the Arabian Gulf in the COVID\u201319 era: focus on disease\u2013modifying therapies and vaccination against COVID\u201319","volume":"10","author":"Inshasi","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clineuro.2024.108615_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103343","article-title":"Effect of cladribine on COVID\u201319 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis","volume":"57","author":"Brill","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211058298","article-title":"Expert opinion on COVID\u201319 vaccination and the use of cladribine tablets in clinical practice","volume":"14","author":"Rieckmann","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2024.108615_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40120-023-00496-3","article-title":"Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis","volume":"12","author":"Clavelou","year":"2023","journal-title":"Neurol. Ther."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672400502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672400502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:20:43Z","timestamp":1733052043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384672400502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S030384672400502X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108615","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108615"}}